Alternatively, ILC2-derived IL-13 could further influence anti-tumor immunity by allowing the migration of activated dendritic cells to the draining lymph nodes [106], which could further facilitate activation of CD8+ CTLs. The gene discussed is CD8A; the disease is neoplasm.